EcoDrugPlus

60s Ribosomal Protein L37

Ensembl ID : ENSELUG00000024481
Gene Symbol: LOC105006097
3 Cross references
420 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSELUG00000004516
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSELUG00000013603
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSELUG00000013882
Gene Symbol: ADAM17
1 Cross references
208 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSELUG00000026373
Gene Symbol: ADAM17
1 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSELUG00000001677
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSELUG00000023390
Gene Symbol: ADRM1
3 Cross references
193 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSELUG00000017813
Gene Symbol: ADRM1
1 Cross references
198 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSELUG00000004824
Gene Symbol: AKT1
3 Cross references
150 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSELUG00000004541
Gene Symbol: AKT1
3 Cross references
188 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSELUG00000013062
Gene Symbol: AKT2
3 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSELUG00000000498
Gene Symbol: AKT3
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).